LG CNS said on Tuesday it has completed the buildout of Dong-A Socio Group's "AI drug discovery platform" with DAI, an IT affiliate of Dong-A Socio Group. The platform integrates and standardises drug research data and supports key processes from candidate discovery to design and validation using AI. It analyses gene and tissue location data to help identify targets, uses generative AI to design compound structures, and simulates binding and stability in validation.